PHP
DGX icon

Parkman Healthcare Partners’s Quest Diagnostics DGX Stock Holding History

Parkman Healthcare Partners’s Portfolio DGX Stock Details DGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-40,997
Closed -$7.36M – 95
2025
Q2 		$7.36M Sell
40,997
-21,596
-35% -$3.75M 0.85% 44
2025
Q1 		$10.6M Sell
62,593
-27,759
-31% -$4.56M 1.26% 29
2024
Q4 		$13.6M Buy
90,352
+35,352
+64% +$5.5M 1.82% 17
2024
Q3 		$8.54M Buy
+55,000
New +$8.21M 1.09% 33

Other funds holding DGX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Parkman Healthcare Partners's DGX Position: Q3 2025 in Review

Parkman Healthcare Partners sold out of Quest Diagnostics (DGX) in Q3 2025, closing a stake of 40,997 shares — an estimated $7.36M sold.

Parkman Healthcare Partners first reported a position in DGX in Q3 2024 and held it in 4 quarters. The position peaked at $13.6M in Q4 2024. 1,006 funds tracked by Wall St. Rank hold DGX as of Q3 2025.

  • Parkman Healthcare Partners reported no remaining Quest Diagnostics position as of Q3 2025 after selling out during the quarter.
  • Parkman Healthcare Partners sold 40,997 Quest Diagnostics shares in Q3 2025, an estimated $7.36M.
  • Parkman Healthcare Partners first reported a position in Quest Diagnostics in Q3 2024 and held it in 4 quarters.
  • Parkman Healthcare Partners's Quest Diagnostics position peaked at $13.6M in Q4 2024.
  • 1,006 funds tracked by Wall St. Rank held Quest Diagnostics as of Q3 2025.

Based on Parkman Healthcare Partners's 13F filing for Q3 2025, filed 14 Nov 2025.